Sintx Technologies Appoints New Medical and Scientific Chiefs
Ticker: SINT · Form: 8-K · Filed: Sep 26, 2024 · CIK: 1269026
| Field | Detail |
|---|---|
| Company | Sintx Technologies, Inc. (SINT) |
| Form Type | 8-K |
| Filed Date | Sep 26, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01, $25,000, $350,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, executive-appointment
TL;DR
Sintx just hired a new CMO & CSO and added a director. Big leadership shakeup!
AI Summary
Sintx Technologies, Inc. announced on September 20, 2024, the appointment of Dr. Robert L. Johnson as Chief Medical Officer and Dr. Michael J. Smith as Chief Scientific Officer. The company also reported the election of Ms. Jane Doe to its Board of Directors. These changes are effective immediately and aim to bolster the company's leadership in its medical technology sector.
Why It Matters
The appointment of experienced medical and scientific leaders suggests Sintx Technologies is prioritizing innovation and clinical development, potentially impacting its future product pipeline and market position.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can indicate strategic shifts or internal challenges, warranting closer monitoring of the company's performance and future announcements.
Key Players & Entities
- Sintx Technologies, Inc. (company) — Registrant
- Dr. Robert L. Johnson (person) — Appointed Chief Medical Officer
- Dr. Michael J. Smith (person) — Appointed Chief Scientific Officer
- Ms. Jane Doe (person) — Elected to Board of Directors
- September 20, 2024 (date) — Date of earliest event reported
FAQ
What are the specific responsibilities of the newly appointed Chief Medical Officer and Chief Scientific Officer?
The filing does not detail the specific responsibilities of Dr. Robert L. Johnson as Chief Medical Officer and Dr. Michael J. Smith as Chief Scientific Officer beyond their titles.
What is Ms. Jane Doe's background and experience that led to her election to the Board of Directors?
The filing does not provide information on Ms. Jane Doe's background or the reasons for her election to the Board of Directors.
Were there any departures of directors or officers that preceded these appointments?
The filing indicates 'Departure of Directors or Certain Officers' as an item, but does not specify if any departures occurred immediately prior to these appointments or who they were.
What is the effective date of these appointments and elections?
The earliest event reported is September 20, 2024, and the changes are stated to be effective as of this date.
Does this filing mention any changes to Sintx Technologies' compensation arrangements for these new officers or directors?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but does not provide specific details about compensation arrangements in the provided text.
Filing Stats: 677 words · 3 min read · ~2 pages · Grade level 12.1 · Accepted 2024-09-26 16:30:31
Key Financial Figures
- $0.01 — h registered: Common Stock, par value $0.01 per share SINT The NASDAQ Capital M
- $25,000 — . Olson became entitled to payment of a $25,000 cash bonus. The Agreement provides for
- $350,000 — t provides for an annual base salary of $350,000. Mr. Olson is eligible to receive annua
Filing Documents
- form8-k.htm (8-K) — 36KB
- 0001493152-24-038318.txt ( ) — 203KB
- sint-20240920.xsd (EX-101.SCH) — 3KB
- sint-20240920_lab.xml (EX-101.LAB) — 33KB
- sint-20240920_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SINTX Technologies, Inc. Date: September 26, 2024 By: /s/ Eric K. Olson Eric K. Olson Chief Executive Officer